Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k).
Farr A, Effendy I, Frey Tirri B, Hof H, Mayser P, Petricevic L, Ruhnke M, Schaller M, Schaefer APA, Sustr V, Willinger B, Mendling W.
Mycoses. 2021 Jun;64(6):583-602. doi: 10.1111/myc.13248. Epub 2021 Feb 27.
Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis.
MacAlpine J, Lionakis MS.
Cell Host Microbe. 2024 Oct 9;32(10):1654-1667. doi: 10.1016/j.chom.2024.08.018.
Candidiasis (vulvovaginal).
Martin Lopez JE.
BMJ Clin Evid. 2015 Mar 16;2015:0815.
Acute vulvovaginitis.
Shirley RL.
N Engl J Med. 2006 Dec 28;355(26):2791; author reply 2791. doi: 10.1056/NEJMc062854.
Ibrexafungerp to treat acute vulvovaginal candidiasis.
Masone MC.
Nat Rev Urol. 2021 Nov;18(11):638. doi: 10.1038/s41585-021-00522-9.
Clinical practice. Acute vulvovaginitis.
Eckert LO.
N Engl J Med. 2006 Sep 21;355(12):1244-52. doi: 10.1056/NEJMcp053720.
Candidiasis (vulvovaginal).
Spence D.
BMJ Clin Evid. 2010 Jan 5;2010:0815.
Recurrent vulvovaginal candidiasis.
Ringdahl EN.
Mo Med. 2006 Mar-Apr;103(2):165-8.
[Vulvar vestibulitis].
Broso P, Buffetti G, Sacco A.
Minerva Ginecol. 1994 Mar;46(3):109-14.
Ibrexafungerp for the treatment of vulvovaginal candidiasis.
Sobel JD.
Drugs Today (Barc). 2022 Apr;58(4):149-158. doi: 10.1358/dot.2022.58.4.3381586.
